Diadema Partners’s Tvardi Therapeutics TVRD Stock Holding History

Diadema Partners’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,185	Closed	-$85.1K	–	201
2025 Q3	$85.1K	Buy	+2,185	New	+$62.2K	0.02%	121

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Diadema Partners's TVRD Position: Q4 2025 in Review

Diadema Partners sold out of Tvardi Therapeutics (TVRD) in Q4 2025, closing a stake of 2,185 shares — an estimated $85.1K sold.

Diadema Partners first reported a position in TVRD in Q3 2025 and held it in 1 quarter. The position peaked at $85.1K in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.

Diadema Partners reported no remaining Tvardi Therapeutics position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 2,185 Tvardi Therapeutics shares in Q4 2025, an estimated $85.1K.
Diadema Partners first reported a position in Tvardi Therapeutics in Q3 2025 and held it in 1 quarter.
Diadema Partners's Tvardi Therapeutics position peaked at $85.1K in Q3 2025.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.